Contrario Medical Wins FDA Clearance for Cyperus Device
Houston, Texas, USA, November 2, 2026 Contrario Medical, Inc. has announced that it has received U.S. Food and Drug...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Houston, Texas, USA, November 2, 2026 Contrario Medical, Inc. has announced that it has received U.S. Food and Drug...
Lausanne, Switzerland and Copenhagen, Denmark, July 6, 2026 ReproNovo announced that the first participant has been dosed in the...
